- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
HOST and FCC promote telemedicine standards
HOST and FCC promote telemedicine standardsThe lack of telemedicine standards is often cited as one of the main barriers to expansion of the specialty. On July 17 in Washington, DC, the HOST consortium and the Federal Communications Commission
HOST and FCC promote telemedicine standards
The lack of telemedicine standards is often cited as one of the main barriers to expansion of the specialty. On July 17 in Washington, DC, the HOST consortium and the Federal Communications Commission (FCC) will bring together members of standards-developing organizations, government agencies, vendors, and healthcare providers to promote standards for open-architecture telemedicine systems.
"Since HOST was created to promote the deployment of open-architecture healthcare systems, and the FCC wants to encourage the adoption of standards in general, our cooperation makes a lot of sense," said Lewis Lorton, executive director of HOST, a nonprofit consortium created in 1994.
The Food and Drug Administration, the Department of Health and Human Services Office of Women's Health, and the Federal Interagency Joint Working Group on Telemedicine are collaborating in the meeting, which will feature a keynote address from FCC chairman Reed Hundt. Other presentations will focus on obstacles to the diffusion of telemedicine, and breakout groups will discuss specific problem areas.
Telemedicine equipment vendors, healthcare and telemedicine providers, governmental agencies, and the public are invited. For more information, visit HOST's Web site at www.hostnet.org.
New AI-Powered Ultrasound Devices May Enhance Efficiency in Women's Imaging
April 19th 2024One of the features on the new Voluson Signature 20 and 18 ultrasound devices reportedly uses automated AI tools to facilitate a 40 percent reduction in the time it takes to perform second trimester exams.
FDA Approves Fluorescence Imaging System for Detecting Residual Breast Cancer
April 18th 2024The combination of the optical imaging agent Lumisight and the fluorescence imaging device Lumicell Direct Visualization System, collectively known as LumiSystem, reportedly offers 84 percent accuracy with real-time detection of residual breast cancer after lumpectomy procedures.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.
